- Macroeconomic challenges: wars, extreme weather, cybersecurity risks, disinformation, rising living costs, supply chain disruptions.
- Pharmaceutical sector challenges: proposed revision of European pharmaceutical legislation.
- Pharmaceutical sector opportunities: upcoming Strategic Pharmaceutical Industry Plan.
- Livestock sector challenges: demanding animal welfare standards, high production costs, lower animal production, emerging diseases.
- Climate-related risks (detailed analysis in 2024).
Faes Farma, S.A.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Faes Farma, S.A. disclosed greenhouse gas emissions of 7.6K tCO2eq/year (Scope 1 and 2). By scope: Scope 1: 5.0K tCO2e/year; Scope 2: 2.6K tCO2e/year; Scope 3: Screening completed in 2023; detailed calculation in 2024. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
7.6K tCO2eq/year (Scope 1 and 2)
2023
Renewable Energy
42% of electricity from renewable sources
of total energy
Water Usage
166.5K m3/year
2023
Waste
1.4K tons/year
2023
Energy Use
25.6M kWh/year (electricity) 10289929 kWh/year (natural gas)
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 5.0K tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 2.6K tCO2e/year |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | Screening completed in 2023; detailed calculation in 2024 |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 7.6K tCO2eq/year (Scope 1 and 2) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced water consumption by 12% in the last two years.
- Increased waste recovery in Animal Health and Nutrition to 80% (from 58% in 2022).
- Doubled Group’s production of electricity from renewable sources.
- LEED Gold certification for new pharmaceutical plant in Derio (Biscay).
- Study and definition of potential greenhouse gas emission reduction measures.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Specific calculation of Scope 3 key sources in 2024.
- Approval of corporate emissions reduction plan in 2024.
- Registration of Group’s carbon footprint with MITECO in 2024.
- ISO 14001 certification at the new Derio plant in 2024.
🌱 ESG Focus Areas
Environmental ManagementClimate ChangeCircular EconomySustainable Resource UseBiodiversity ProtectionHuman Capital ManagementHealth and SafetySocial RelationsEquality, Diversity and AccessibilityResponsible Supply ChainCorporate GovernanceEthics and IntegrityPatient and User Health